0001127602-23-018065.txt : 20230606
0001127602-23-018065.hdr.sgml : 20230606
20230606165930
ACCESSION NUMBER: 0001127602-23-018065
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230605
FILED AS OF DATE: 20230606
DATE AS OF CHANGE: 20230606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sullivan Timothy Eugene
CENTRAL INDEX KEY: 0001707000
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 23996792
MAIL ADDRESS:
STREET 1: 800 BOYLSTON ST., SUITE 3310
STREET 2: PRUDENTIAL TOWER C/O AJU IB INVESTMENT
CITY: BOSTON
STATE: MA
ZIP: 02199
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0407
4
2023-06-05
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001707000
Sullivan Timothy Eugene
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
Chief Financial Officer
1
Common Stock
56232
I
The Timothy E Sullivan Irrevocable Trust of 2023
Common Stock
2023-06-05
4
M
0
69779
10.03
A
147492
D
Common Stock
2023-06-05
4
S
0
1600
90.6044
D
145892
D
Common Stock
2023-06-05
4
S
0
30609
87.7886
D
115283
D
Common Stock
2023-06-05
4
S
0
7064
88.3649
D
108219
D
Common Stock
2023-06-05
4
S
0
30506
89.8259
D
77713
D
Stock Option (Right to Buy)
10.03
2023-06-05
4
M
0
69779
0
D
2027-10-18
Common Stock
69779
288840
D
The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
This is a scheduled exercise & sale from 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $90.380 - $90.790. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $87.155 - $88.150. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $88.160 - $89.130. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $89.375 - $90.370. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on October 18, 2017 and fully vested.
/s/s David Watson, attorney-in-fact for Timothy Sullivan
2023-06-06